IDPS HomeInfectious Diseases A-CD-GH-LM-QR-ST-ZDisease ReportingEmerging and Acute Infectious Disease UnitHealthcare SafetyIDPS Health TopicsRelated DSHS SitesRelated Rules & RegulationsZoonosis Control BranchAbout IDPS
  • Contact Us

    Infectious Disease Prevention Section
    Mail Code: 1927
    PO BOX 149347 - Austin, TX 78714-9347
    1100 West 49th Street, Suite G401
    Austin, TX 78714

    Phone: (512) 776-7676
    Fax: (512) 776-7616


    E-mail

Monkeypox

Data   Investigation    Reporting    Resources

Organism, Causative agent, Etiologic agent

The infectious agent of monkeypox disease is the monkeypox virus, a species in the genus Orthopoxvirus and the family Poxviridae.

Transmission Routes

Monkeypox virus can spread when a person comes into contact with the virus from an infected animal, infected person, or materials contaminated with the virus. The virus can also cross the placenta from the mother to the fetus.

Person-to-person transmission of monkeypox is primarily through direct contact with infectious lesions, scabs, or body fluids. However, respiratory secretions can also transmit the virus. Examples of activities that may spread monkeypox from one person to another are wrestling, cuddling, kissing, or intimate sexual contact, including oral, anal, and vaginal sex, massage, mutual masturbation, or touching fabrics and objects that a person with monkeypox used during sex. At this time, it is not known if monkeypox can spread through semen or vaginal fluids.

Furthermore, the monkeypox virus may spread from animals to people through the bite or scratch of an infected animal, handling wild game, or using products made from infected animals. It is unknown what animal maintains the virus in nature, although African rodents are suspected of being involved in monkeypox transmission to people.

Signs and Symptoms

Monkeypox is a severe acute illness, usually with sudden onset of initial symptoms of fever, headache, muscle aches, backache, swollen lymph nodes (lymphadenopathy), chills, and exhaustion. Clinically, the disease closely resembles smallpox, but lymphadenopathy is a more prominent feature in the early stage of monkeypox disease.

Shortly afterwards, a rash develops, usually starting on the face and spreading to other body parts. Lesions typically begin to form simultaneously and evolve together on any part of the body as they progress from small red bumps to larger pus-filled bumps to scabs before falling off. Monkeypox may not always appear the same way and could be clinically confused with a chickenpox or shingles (varicella zoster virus) or a sexually transmitted infection (STI) like syphilis or herpes. The illness typically lasts for 2−4 weeks. In Africa, monkeypox has been shown to cause death in as many as 1 in 10 persons who contract the disease. If someone has a very weak immune system, then the rash and illness could present differently.

The incubation period (time from infection to symptoms) for monkeypox is usually 7−14 days but can range from 5−21 days. The rash typically begins within 5 days of the first symptoms.

Prevention

People can take several measures to prevent infection with the monkeypox virus:

  • Avoid contact with people who have a new or unknown rash, lesions, or scabs. This contact can happen during activities such as wrestling, cuddling, or intimate sexual contact.
  • Avoid contact with animals that could harbor the virus, such as prairie dogs, rabbits, rope squirrels, Gambian rats, wallabies, and African tree squirrels. This includes sick or dead animals from areas where monkeypox is endemic (Central or West Africa).
  • Avoid contact with any materials, such as bedding that has been in contact with a sick person or animal.
  • Isolate infected patients from others who could be at risk for infection. For example, after consulting with your local or state health department, patients who do not require hospitalization for medical indications may be isolated at home using protective measures. 
  • Use personal protective equipment (PPE) and follow standard donning and doffing procedures when caring for patients. PPE used by healthcare personnel who enter the patient’s room should include a gown, gloves, eye protection (i.e., goggles or a face shield covering the front and sides of the face), NIOSH-approved N95 filtering facepiece or equivalent, or a higher-level respirator. 
  • Practice good hand hygiene after contact with infected animals or humans. For example, washing your hands with soap and water or using an alcohol-based hand sanitizer, when soap and water are not available.
  • JYNNEOS (also known as Imvamune or Imvanex) is an attenuated live virus vaccine approved by the U.S. Food and Drug Administration to prevent monkeypox. On November 3, 2021, The Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend JYNNEOS pre-exposure prophylaxis as an alternative to the live smallpox vaccine ACAM2000 for certain persons at risk for exposure to orthopoxviruses. ACIP evaluated JYNNEOS to protect research laboratory personnel, clinical laboratory personnel performing diagnostic testing for orthopoxviruses, designated response team members, and health care personnel who administer ACAM2000 or care for patients infected with orthopoxviruses.

Therapeutics 

Currently, there is no specific treatment approved for monkeypox virus infections. However, antivirals developed for use in patients with smallpox may prove beneficial. These medical countermeasures are currently available from the Strategic National Stockpile (SNS).

Texas Trends 

In 2021 there was one confirmed case of monkeypox in Texas associated with the ongoing outbreak in West African countries. As of July 1, 2022, Texas has reported multiple cases of monkeypox. A current map of the cases reported in the United States can be found on the CDC’s website (U.S. Monkeypox 2022: Situation Summary).


In May 2022, in response to the multi-country outbreak of monkeypox in non-endemic countries, the Centers for Disease Control and Prevention (CDC) and the Texas Department of State Health Services (DSHS), along with local and regional public health departments, have implemented enhanced surveillance measures to identify cases of monkeypox in Texas quickly. These measures include providing education and outreach to public health agencies and clinicians in Texas, evaluating persons with suspicion of monkeypox, and monitoring contacts of confirmed cases for symptom development. 

Monkeypox Health Alert 2022

Last updated July 1, 2022